ATLANTA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that the 3-year results of the PALADIN study have been published in the peer-reviewed journal Ophthalmology.
Read more at globenewswire.comPhase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
